IRB #

IRB00011688

Title

A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients with Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

To establish a safe dose of the study drug (LOXO-101) by gathering information on how well it is tolerated, any potential side effects it may cause, and collecting data about how your cancer responds to the drug.

Medical Condition(s)

All solid tumors.

Eligibility Criteria

1. Female or male 18 years or older
2. Any solid tumor
3. Other criteria also apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression, unacceptable side effects, or participant's decision to withdraw from the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Loxo Oncology Inc

Recruitment End

12/31/2018

Compensation Provided

No


Go Back